PHASE II MULTICENTER TRIAL OF INTRATUMORAL/INTERSTITIAL THERAPY--BRAIN TUMORS

瘤内/间质治疗的II期多中心试验——脑肿瘤

• 批准号: 6280085
• 负责人: SUNIL J PATEL
• 金额: $ 2.73万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-12-01 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6280085
• 关键词: brain neoplasms; clinical research; diphtheria toxin; drug administration routes; drug screening /evaluation; human subject; human therapy evaluation; immunotoxicity; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neurotoxicology; transferrin

HN-66000 is a proprietary pharmaceutical formulation of mutant diptheria toxin (CRM 107) and human transferrin(Tf) that is being developed as a potential treat ment for malignant brain tumors. The results for a Phase I trial with HN-66000, sponsored by the NIH, suggest that HN-66000 produces tumor responses in patients with malignant brain tumors refractory to conventional therapy without severe neurologic or systemic toxicity. These encouraging results warrant an expanded evaluation of HN-66000 at other centers in a Phase II trial.

HN-66000是一种突变白喉的专利药物配方 毒素(CRM107)和人转铁蛋白(Tf)正在作为一种 恶性脑瘤的潜在治疗方法。一个阶段的结果 我用由美国国立卫生研究院赞助的HN-66000进行了试验，建议HN-66000 在恶性脑肿瘤患者中产生肿瘤反应 在没有严重的神经系统或全身性疾病的情况下，常规治疗难以奏效 毒性。这些令人鼓舞的结果需要扩大对 HN-66000在其他中心进行第二阶段试验。